Literature DB >> 16027255

Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets.

Chris van der Lee1, Folkert J ten Cate, Marcel L Geleijnse, Marcel J Kofflard, Chiara Pedone, Lex A van Herwerden, Elena Biagini, Wim B Vletter, Patrick W Serruys.   

Abstract

BACKGROUND: The purpose of this study was to compare percutaneous transluminal septal myocardial ablation (PTSMA) and septal myectomy combined with mitral leaflet extension (MLE) in symptomatic hypertrophic obstructive cardiomyopathy patients with an enlarged anterior mitral valve leaflet (AMVL). Both PTSMA and myectomy reduce septal thickness and left ventricular outflow tract (LVOT) gradient; however, an uncorrected enlarged AMVL may predispose to residual systolic anterior motion (SAM) after successful standard myectomy or PTSMA. Myectomy with MLE previously demonstrated superior hemodynamic results compared with standard myectomy, but its value relative to PTSMA is unknown. METHODS AND
RESULTS: Twenty-nine patients (aged 44+/-12 years) underwent myectomy with MLE, and 43 patients (aged 52+/-17 years) underwent PTSMA. Mitral leaflet area was similar in both groups (16.7+/-3.4 versus 15.9+/-2.7 cm2, respectively). After PTSMA, 2 patients died, 4 needed a reintervention, and 4 required a permanent pacemaker for complete heart block. After surgery, only 1 patient needed a reintervention. At 1-year follow-up, LVOT gradients did not differ between surgical and PTSMA patients (17+/-14 versus 23+/-19 mm Hg, respectively). Preinterventional mitral regurgitation grade was more severe in the surgical group, but with myectomy combined with MLE, the residual grade was similar to that of PTSMA. Mean SAM grade decreased significantly more after surgery (from 2.9+/-0.3 to 0.5+/-0.7 mm Hg versus from 2.8+/-0.5 to 1.3+/-0.9 [corrected], P<0.05).
CONCLUSIONS: PTSMA in these selected patients with hypertrophic obstructive cardiomyopathy had more periprocedural complications and resulted in more reinterventions. Hemodynamic results (SAM grade and reduction in mitral regurgitation) were better in surgical patients.

Entities:  

Mesh:

Year:  2005        PMID: 16027255     DOI: 10.1161/CIRCULATIONAHA.104.508309

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

Review 1.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  Long-term outcome of simultaneous septal myectomy and anterior mitral leaflet retention plasty in hypertrophic obstructive cardiomyopathy: the Berlin experience.

Authors:  Eva Maria Delmo Walter; Mariano Francisco Javier; Roland Hetzer
Journal:  Ann Cardiothorac Surg       Date:  2017-07

3.  Is surgery the gold standard in the treatment of obstructive hypertrophic cardiomyopathy?

Authors:  Gennady Knyshov; Vasyl Lazoryshynets; Kostyantyn Rudenko; Borys Kravchuk; Vyacheslav Beshlyaga; Valery Zalevsky; Olga Rasputnyak; Bogdan Batsak
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-09-30

4.  Surgical outcomes and strategy of hypertrophic obstructive cardiomyopathy.

Authors:  Ya-bin Zhu; S Rajan; V M Kurian; Zhi-yong Liu
Journal:  J Zhejiang Univ Sci B       Date:  2006-02       Impact factor: 3.066

Review 5.  Sudden death in hypertrophic cardiomyopathy.

Authors:  Barry J Maron
Journal:  J Cardiovasc Transl Res       Date:  2009-11-13       Impact factor: 4.132

Review 6.  Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy.

Authors:  Elizabeth Packard; Alejandro de Feria; Supriya Peshin; Nosheen Reza; Anjali Tiku Owens
Journal:  Cardiol Ther       Date:  2022-10-15

Review 7.  Review of Contemporary Invasive Treatment Approaches and Critical Appraisal of Guidelines on Hypertrophic Obstructive Cardiomyopathy: State-of-the-Art Review.

Authors:  Steven Lebowitz; Mariusz Kowalewski; Giuseppe Maria Raffa; Danny Chu; Matteo Greco; Caterina Gandolfo; Carmelo Mignosa; Roberto Lorusso; Piotr Suwalski; Michele Pilato
Journal:  J Clin Med       Date:  2022-06-14       Impact factor: 4.964

8.  Therapeutic options in hypertrophic cardiomyopathy: a pediatric perspective.

Authors:  Edward K Rhee; John J Nigro; Stephen G Pophal
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-09

9.  A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy.

Authors:  Attilio Iacovoni; Paolo Spirito; Caterina Simon; Maria Iascone; Giovanni Di Dedda; Paolo De Filippo; Samuele Pentiricci; Luca Boni; Michele Senni; Antonello Gavazzi; Paolo Ferrazzi
Journal:  Eur Heart J       Date:  2012-04-20       Impact factor: 29.983

Review 10.  Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy.

Authors:  Martin S Maron
Journal:  J Cardiovasc Magn Reson       Date:  2012-02-01       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.